Curaleaf (OTCMKTS:CURLF – Get Free Report) issued its earnings results on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.25, Zacks reports. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. The company had revenue of $340.10 million during the quarter, compared to analyst estimates of $332.00 million.
Curaleaf Stock Performance
CURLF stock traded up $0.65 during mid-day trading on Thursday, reaching $9.00. 106,119 shares of the stock traded hands, compared to its average volume of 312,862. The firm has a market capitalization of $2.10 billion, a PE ratio of -23.07 and a beta of 1.56. The business has a 50-day moving average of $7.04 and a two-hundred day moving average of $7.68. Curaleaf has a 52 week low of $4.56 and a 52 week high of $15.15. The company has a quick ratio of 0.74, a current ratio of 1.56 and a debt-to-equity ratio of 1.05.
Analyst Ratings Changes
CURLF has been the subject of a number of research reports. Citigroup reissued a “buy” rating on shares of Curaleaf in a research report on Thursday. Zacks Research upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Three equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat.com, Curaleaf currently has an average rating of “Strong Buy”.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Featured Stories
- Five stocks we like better than Curaleaf
- McDonald’s Stock Sell-Off: Justified Warning or Buying Opportunity?
- Why Brown-Forman Rejected a 23% Premium Twice
- Rocket Lab Lands a Wave of Contracts Ahead of Earnings
- Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
